<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The combination of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A (MTX-CSA) is the standard regimen for the prevention of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft vs. host disease</z:e> (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-SCT) from HLA-identical siblings </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="168396">Mycophenolate</z:chebi> mofetil and CSA (MMF-CSA) combination has been successfully used for GVHD prophylaxis after non-reduced intensity conditioning (non-RIC) allo-SCT with peripheral blood or non-G-CSF stimulated bone marrow as stem cell source </plain></SENT>
<SENT sid="2" pm="."><plain>We report the results of the first prospective trial of the MMF-CSA combination for <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD prophylaxis in 47 patients after non-RIC G-CSF stimulated allo-BMT (G-BMT) from HLA-identical siblings in patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) or <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Median age was 28 yr (range, 6-48 yr) </plain></SENT>
<SENT sid="4" pm="."><plain>Median follow-up was 22 months </plain></SENT>
<SENT sid="5" pm="."><plain>The median time to neutrophil and platelets recovery were nine d (range, 8-17) and 16 d (range, 10-28), respectively </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD of grade II-IV and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD occurred in 51% and 27%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Overall survival rates at two yr for patients with SAA and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> were 87% and 65%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The event-free survival at two yr for patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> was 76% </plain></SENT>
<SENT sid="9" pm="."><plain>We concluded that MMF-CSA appears equivalent to MTX-CSA for GVHD prophylaxis in patients receiving non-RIC G-BMT from HLA-identical siblings, with a tendency for more rapid neutrophil engraftment </plain></SENT>
</text></document>